New sPCR Technology Runs on Standard Devices
|
By LabMedica International staff writers Posted on 24 Apr 2017 |

Image: A comparison of analytical PCR procedures (Photo courtesy of Scientific Reports).
Synergistic PCR (sPCR), a new method of DNA analysis developed for use on a new high-speed assay device, can also be carried out on widely available laboratory real-time PCR (qPCR) instruments and does not require calibration.
While developing a record high-speed genetic research tool, Curiosity Diagnostics (CD; Warsaw, Poland), a spinoff company of the Warsaw Institute of Physical Chemistry of the Polish Academy of Sciences (IPC PAS) and part of the Scope Fluidics group, has developed the new sPCR method, which combines key advantages of the two currently most used methods.
"The DNA assay technique we propose was born during the development of the innovative PCR|ONE analytical instrument, which can be used to test the genetic code in only 7 minutes. This is more than 10-fold shorter time than is required in classic solutions," said Prof. Piotr Garstecki (IPC PAS, CD).
PCR is used both to detect specific DNA fragments and to estimate the original amount of genetic material. In quantitative PCR (qPCR) measurements are usually carried out using real-time PCR – an analogue technique. Due to the sensitivity of PCR to even single particles of impurities, qPCR requires careful, continuous calibration. Conversely, in digital PCR (dPCR) there is no need to calibrate the device, however, because of the need to conduct a large number of reactions in parallel, the testing equipment is expensive and is not as common in laboratories as the analogue apparatus.
sPCR combines the most important advantages of analogue and digital methods to obtain reliable measurements: it is sufficient to dilute a sample into only a dozen or at most several dozen partitions, and calibration is not required.
"A small number of partitions, characteristic of our technique, are of specific practical significance. It means that to perform the analysis all that is needed is the standard well plate format used in popular analogue PCR devices," said Pawel Debski, an IPC PAS PhD student who developed the sPCR method with Curiosity Diagnostics.
Also due to a small number of sample partitions, the sPCR technique is easier to perform and slightly faster than digital variants. Compared to analogue techniques, however, more reagents are required, and so it will not replace the analogue variant. Nevertheless, sPCR could be a valuable addition, as it requires no calibration and so will allow laboratory staff to independently and regularly check the correctness of analogue measurements.
sPCR was developed as an integral component of PCR|ONE, an innovative device designed for rapid DNA analysis. In standard PCR machines, relatively slow heat diffusion between the sample and an adjacent large block of alternately heated or cooled material is used to heat and cool the genetic material. In PCR|ONE, infrared radiation is used to heat the sample rapidly. The diffusion cooling mechanism has also been modified: the block used for this purpose is smaller than in conventional instruments and it is maintained at a constant, strictly controlled temperature. As a result of the technical and analytical improvements, the currently being tested prototypes of PCR|ONE are able to complete DNA assays in less than 15 minutes, and the PCR itself takes only 7 minutes. The first PCR|ONE devices are expected to be commercially available in 2-3 years.
"Our DNA testing technique has been patented. However, we want to emphasize the freedom of using it for non-commercial purposes," said Prof. Garstecki.
The study, by Debski PR et al, was published March 22, 2017, in the journal Scientific Reports.
While developing a record high-speed genetic research tool, Curiosity Diagnostics (CD; Warsaw, Poland), a spinoff company of the Warsaw Institute of Physical Chemistry of the Polish Academy of Sciences (IPC PAS) and part of the Scope Fluidics group, has developed the new sPCR method, which combines key advantages of the two currently most used methods.
"The DNA assay technique we propose was born during the development of the innovative PCR|ONE analytical instrument, which can be used to test the genetic code in only 7 minutes. This is more than 10-fold shorter time than is required in classic solutions," said Prof. Piotr Garstecki (IPC PAS, CD).
PCR is used both to detect specific DNA fragments and to estimate the original amount of genetic material. In quantitative PCR (qPCR) measurements are usually carried out using real-time PCR – an analogue technique. Due to the sensitivity of PCR to even single particles of impurities, qPCR requires careful, continuous calibration. Conversely, in digital PCR (dPCR) there is no need to calibrate the device, however, because of the need to conduct a large number of reactions in parallel, the testing equipment is expensive and is not as common in laboratories as the analogue apparatus.
sPCR combines the most important advantages of analogue and digital methods to obtain reliable measurements: it is sufficient to dilute a sample into only a dozen or at most several dozen partitions, and calibration is not required.
"A small number of partitions, characteristic of our technique, are of specific practical significance. It means that to perform the analysis all that is needed is the standard well plate format used in popular analogue PCR devices," said Pawel Debski, an IPC PAS PhD student who developed the sPCR method with Curiosity Diagnostics.
Also due to a small number of sample partitions, the sPCR technique is easier to perform and slightly faster than digital variants. Compared to analogue techniques, however, more reagents are required, and so it will not replace the analogue variant. Nevertheless, sPCR could be a valuable addition, as it requires no calibration and so will allow laboratory staff to independently and regularly check the correctness of analogue measurements.
sPCR was developed as an integral component of PCR|ONE, an innovative device designed for rapid DNA analysis. In standard PCR machines, relatively slow heat diffusion between the sample and an adjacent large block of alternately heated or cooled material is used to heat and cool the genetic material. In PCR|ONE, infrared radiation is used to heat the sample rapidly. The diffusion cooling mechanism has also been modified: the block used for this purpose is smaller than in conventional instruments and it is maintained at a constant, strictly controlled temperature. As a result of the technical and analytical improvements, the currently being tested prototypes of PCR|ONE are able to complete DNA assays in less than 15 minutes, and the PCR itself takes only 7 minutes. The first PCR|ONE devices are expected to be commercially available in 2-3 years.
"Our DNA testing technique has been patented. However, we want to emphasize the freedom of using it for non-commercial purposes," said Prof. Garstecki.
The study, by Debski PR et al, was published March 22, 2017, in the journal Scientific Reports.
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







